gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Fibroblast growth factor receptor 4

FGFR4, fibroblast growth factor receptor 4
The protein encoded by this gene is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. The genomic organization of this gene, compared to members 1-3, encompasses 18 exons rather than 19 or 20. Although alternative splicing has been observed, there is no evidence that the C-terminal half of the IgIII domain of this protein varies between three alternate forms, as indicated for members 1-3. This particular family member preferentially binds acidic fibroblast growth factor and, although its specific function is unknown, it is overexpressed in gynecological tumor samples, suggesting a role in breast and ovarian tumorigenesis. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: FGFR1, FGFR3, FGFR2, CAN, Fibroblast Growth Factor 2
Papers using FGFR4 antibodies
A road map for those who don't know JAK-STAT.
Bereswill Stefan, In PLoS ONE, 2001
... The following antibodies were used: ACTIN, FGFR1, FGFR2, FGFR3 and FGFR4 (Santa Cruz Biotechnology, Santa Cruz, CA); ERK1/2, ...
Papers on FGFR4
FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.
Mailleux et al., Paris, France. In Am J Physiol Lung Cell Mol Physiol, Feb 2016
In vitro, HLFs mainly expressed mesenchyme-associated FGFR isoforms (FGFR1c and FGFR3c) and FGFR4.
Fibroblast growth factor receptor 4: the missing link between chronic kidney disease and FGF23-induced left ventricular hypertrophy?
Drüeke et al., New York City, United States. In Kidney Int, Jan 2016
A recent study identified fibroblast growth factor receptor 4 as the primary receptor mediating the effect of fibroblast growth factor 23 on left ventricular hypertrophy, providing new mechanistic insights and a potential therapeutic target to reduce cardiovascular morbidity in chronic kidney disease.
Germline variant FGFR4  p.G388R exposes a membrane-proximal STAT3 binding site.
Ullrich et al., Martinsried, Germany. In Nature, Jan 2016
Variant rs351855-G/A is a commonly occurring single-nucleotide polymorphism of coding regions in exon 9 of the fibroblast growth factor receptor FGFR4 (CD334) gene (c.1162G>A).
An FGFR4 Germline Variant Activates STAT3 Signaling.
In Cancer Discov, Jan 2016
UNASSIGNED: An FGFR4 substitution promotes STAT3 signaling by revealing a membrane-proximal STAT3 binding site.
Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
Haffner et al., Hannover, Germany. In Nephrol Dial Transplant, Jan 2016
Cardiac FGF23 levels associate with time-averaged serum phosphate levels, up-regulation of FGFR4 and activation of the calcineurin-NFAT signaling pathway, an established mediator of cardiac remodelling and LVH.
Efficacy of fibroblast growth factor (FGF) on epithelialization of the neovagina in patients with Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) who underwent vaginoplasty.
Sakakibara et al., Yokohama, Japan. In J Pediatr Adolesc Gynecol, Jan 2016
Among the FGFR subtypes, FGFR-4 was overexpressed during the process of epithelialization and its level decreased after completion of creation of the new vagina.
FGF signalling regulates bone growth through autophagy.
Settembre et al., Pozzuoli, Italy. In Nature, Jan 2016
Surprisingly, post-natal induction of chondrocyte autophagy is mediated by the growth factor FGF18 through FGFR4 and JNK-dependent activation of the autophagy initiation complex VPS34-beclin-1.
Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy.
Faul et al., Miami, United States. In Cell Metab, Jan 2016
Here, we report that FGF23 exclusively activates FGFR4 on cardiac myocytes to stimulate phospholipase Cγ/calcineurin/nuclear factor of activated T cell signaling.
Targeting fibroblast growth factor receptor pathway in breast cancer.
Curigliano et al., Napoli, Italy. In Curr Opin Oncol, Nov 2015
Moving forward, the design and development of FGFR4 inhibitors and covalent FGFR inhibitors may overcome resistance to first-generation FGFR inhibitors.
FGF23 regulation of renal tubular solute transport.
Andrukhova et al., Vienna, Austria. In Curr Opin Nephrol Hypertens, Sep 2015
RECENT FINDINGS: Recent evidence suggests that FGF23 suppresses phosphate reabsorption in renal proximal tubular epithelium by a Klotho-dependent, FGF receptor (FGFR)-1 and FGFR4-mediated signaling mechanism that may also involve Janus kinase 3.
Targeting fibroblast growth factor 19 in liver disease: a potential biomarker and therapeutic target.
Zheng et al., Wenzhou, China. In Expert Opin Ther Targets, May 2015
The molecular pathway of the FGF19-FGFR4 axis in non-alcoholic liver disease and hepatocellular carcinoma are discussed.
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Poupon et al., Amsterdam, Netherlands. In J Hepatol, Apr 2015
The membrane receptors fibroblast growth factor receptor 4 (FGFR4) and apical sodium BA transporter (ASBT) deserve attention as additional therapeutic targets, as does the potential therapeutic agent norUDCA, a 23-C homologue of UDCA.
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer.
Cortés et al., Villejuif, France. In Breast Cancer Res Treat, Feb 2015
In breast cancers, FGFR1 and FGFR4 gene amplification and single nucleotide polymorphisms in FGFR2 and FGFR4 have been detected.
Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis.
Feng et al., San Diego, United States. In Cell Metab, 2014
Ablating Shp2 in hepatocytes suppressed signal relay from FGFR4, receptor for FGF15/19, and attenuated BA activation of FXR signaling, resulting in elevation of systemic BA levels and chronic hepatobiliary disorders in mice.
The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.
Asa et al., Toronto, Canada. In Cell Metab, 2013
The fibroblast growth factor receptor 4 (FGFR4)-R388 single-nucleotide polymorphism has been associated with cancer risk and prognosis.
Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Mercado et al., Mexico. In J Clin Endocrinol Metab, 2012
Determination of the expression of FGFR4 in an attempt to establish correlations and/or associations with clinical characteristics of patients with nonfunctioning pituitary adenomas.
Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinoma.
Ho et al., Singapore, Singapore. In Mol Cancer, 2011
KLB-silencing in Huh7 cells decreased cell proliferation and suppressed FGFR4 downstream signaling.
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Luo et al., Houston, United States. In Plos One, 2011
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Fibroblast growth factor receptor 4 Gly388Arg polymorphism associated with severity of gallstone disease in a Chinese population.
Li et al., Xiamen, China. In Genet Mol Res, 2011
the FGFR4 polymorphism is a genetic risk factor contributing to aggravation of gallstone disease.
Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
Desnoyers et al., San Francisco, United States. In Plos One, 2011
findings suggest a modulatory role for FGFR4 in the development and progression of hepatocellular carcinoma and that FGFR4 may be an important and novel therapeutic target in treating this disease
share on facebooktweetadd +1mail to friends